
GSK acquires efimosfermin alfa from Boston Pharma for $2bn
GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal. The transaction includes an upfront payment of $1.2bn and potential milestone payments of $ …